Skip to main content
Figure 1 | BMC Research Notes

Figure 1

From: Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

Figure 1

Cell proliferation assay (MTS) to determine IC 50 of single agent and combination treatments in HS-SY-II and SYO-I. A and C, representative dose–response curves of HS-SY-II (A) and SYO-I (C) treated with ridaforolimus, vorinostat, doxorubicin, and melphalan. B and D, graphs representing the mean ± SE IC50 values for single agents and combination treatments in HS-SY-II (B) and SYO-I (D) from at least 3 independent experiments. *Indicates statistical significance of p < 0.05.

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us